Novo CEO Mike Doustdar pushes semaglutide from weight loss into longevity and aesthetics
Novo is asking scientists to chase benefits outside the scale, and that could reshape its strategy as competition bites.
By Khalid Al-Harbi·· 4 min
1 briefing · “semaglutide”
Novo is asking scientists to chase benefits outside the scale, and that could reshape its strategy as competition bites.